This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Specified Drug Use-Results Survey of Regnite

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Astellas Pharma Inc
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: June 25, 2013
Last updated: June 14, 2017
Last verified: June 2017
This study is to investigate the long-term safety and efficacy and the information on the proper use of Regnite® under conditions of daily clinical use.

Condition Intervention
Restless Legs Syndrome Drug: Regnite

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Specified Drug Use-Results Survey of Regnite

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Safety such as occurrence of adverse drug reactions and lab-tests [ Time Frame: Up to 52 weeks ]

Secondary Outcome Measures:
  • Restless Leg Syndrome score [ Time Frame: Baseline and at 52 weeks ]
  • Clinical Global Impression [ Time Frame: Baseline and at 52 weeks ]

Estimated Enrollment: 1500
Actual Study Start Date: October 1, 2012
Estimated Study Completion Date: January 2019
Estimated Primary Completion Date: January 2019 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Regnite group
Patients who receive Regnite
Drug: Regnite
Other Name: gabapentin enacarbil

Detailed Description:
Sleeping condition and severity of restless legs syndrome (RLS) were recorded at the start and during the treatment. The treatment period is scheduled to last 52 weeks in principle. For patients completing or discontinuing the use of Regnite® within 52 weeks, follow up on the withdrawal and rebound syndrome will be conducted up to 4 weeks of completion or discontinuation.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with moderate to severe idiopathic restless legs syndrome

Inclusion Criteria:

  • Patients with moderate to severe idiopathic restless legs syndrome

Exclusion Criteria:

  • Patients with a history of hypersensitivity to any ingredients in Regnite or gabapentin
  • Patients with severely impaired renal function (creatinine clearance of less than 30 mL/min)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01887613

Contact: Clinical Development Administration

Chubu, Japan
Hokkaido, Japan
Kansai, Japan
Kantou, Japan
Kyushu, Japan
Shikoku, Japan
Touhoku, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Study Chair: Use Central Contact Astellas Pharma Inc
  More Information

Responsible Party: Astellas Pharma Inc Identifier: NCT01887613     History of Changes
Other Study ID Numbers: REG001
Study First Received: June 25, 2013
Last Updated: June 14, 2017

Keywords provided by Astellas Pharma Inc:

Additional relevant MeSH terms:
Restless Legs Syndrome
Nervous System Diseases
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Mental Disorders
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Antimanic Agents processed this record on September 21, 2017